血栓与否?腺病毒相关疫苗诱导免疫性血栓性血小板减少症机制探讨
疫苗诱导免疫性血栓性血小板减少症(VITT)在接种腺病毒载体新冠疫苗后出现血栓与重度血小板减少。本文讨论腺病毒诱导VITT的潜在机制并提出待研究问题。
要点
- VITT见于接种ChAdOx1 nCov-19和Ad26.COV2.S疫苗后,表现为血栓伴重度血小板减少。
- 典型表现:首剂后5-24天出现血栓、血小板减少、D-二聚体升高及PF4抗体。
- 腺病毒诱导VITT的确切致病机制尚未完全阐明,需进一步研究。
核心结论
- VITT与腺病毒载体新冠疫苗相关,其致病机制尚未完全阐明,本文提出潜在机制假设与研究方向。
研究设计与样本
- 本文为机制探讨性综述,未报告系统检索范围与纳入研究数量。
主要发现
- 英国、欧洲、加拿大和澳大利亚共报告467例VITT病例,占比0.000024%。
- VITT患者表现为血栓、首剂疫苗后5-24天出现的重度血小板减少、D-二聚体升高及提示血小板活化的PF4抗体。
临床怎么用
- 诊断与管理已有相关指南报告,但需结合腺病毒载体疫苗接种史识别VITT。
局限性
- VITT的致病机制尚未完全阐明,仍需进一步研究以确立致病模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-induced immune thrombotic thrombocytopenia (VITT) has caused global concern. VITT is characterized by thrombosis and thrombocytopenia following COVID-19 vaccinations with the AstraZeneca ChAdOx1 nCov-19 and the Janssen Ad26.COV2.S vaccines. Patients present with thrombosis, severe thrombocytopenia developing 5-24 days following first dose of vaccine, with elevated D-dimer, and PF4 antibodies, signifying platelet activation. As of June 1, 2021, more than 1.93 billion COVID-19 vaccine doses had been administered worldwide. Currently, 467 VITT cases (0.000024%) have been reported across the UK, Europe, Canada, and Australia. Guidance on diagnosis and management of VITT has been reported but the pathogenic mechanism is yet to be fully elucidated. Here, we propose and discuss potential mechanisms in relation to adenovirus induction of VITT. We provide insights and clues into areas warranting investigation into the mechanistic basis of VITT, highlighting the unanswered questions. Further research is required to help solidify a pathogenic model for this condition.
引用
- Othman M, Baker AT, Gupalo E, et al. To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia. J Thromb Haemost. 2021. PMID: 34351057. doi:10.1111/jth.15485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。